SolAeroMed is now recruiting Cystic Fibrosis patients for a drug study.


Participate in a Phase IIa trial for a novel mucolytic/bronchodilator drug (S-1226).

In 2015, SolAeroMed successfully completed a Phase I study, demonstrating that S-1226 drug is both safe and tolerable in healthy human patients. The two parts of the S-1226 drug, perflubron and CO2, have been shown to have mucolytic and bronchodilatory effects in lungs in both animals, and humans. The drug saw success in treating symptoms in acute asthma patients.

Today there is an exciting opportunity to participate in Phase IIa clinical trial, which will test the effect of S-1226 in Cystic Fibrosis patients. The goal of the study is to determine whether daily use of S-1226 can improve mucous clearance and relieve the airway constriction in CF patients. The study has been approved by Health Canada and SolAeroMed is currently in the process of recruiting CF patients in Calgary between ages 14 and 50.

If you or someone you know suffer from Cystic Fibrosis, signing up for the study is a great opportunity to contribute to groundbreaking research that will help thousands of Cystic Fibrosis patients with treating their symptoms.

top